Aligos Therapeutics (ALGS) Net Shares Issued and Repurchased (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Net Shares Issued and Repurchased for 8 consecutive years, with $439335.0 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Net Shares Issued and Repurchased rose 6.91% year-over-year to $439335.0; the trailing twelve-month figure through Mar 2026 stood at $439335.0 (up 6.91% YoY), and the FY2025 full-year result was $1.2 million, up 222.84% from the prior year.
• Net Shares Issued and Repurchased fell to $439335.0 in Q1 2026 per ALGS's latest filing, from $1.2 million in the prior quarter.
• Across five years, Net Shares Issued and Repurchased topped out at $5.1 million in Q4 2022 and bottomed at $359135.0 in Q4 2024.
• Historically, Net Shares Issued and Repurchased has averaged $2.0 million across 5 years, with a median of $1.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Net Shares Issued and Repurchased jumped 6022.39% in 2022, then slumped 85.76% in 2025.
• Over 5 years, Net Shares Issued and Repurchased stood at $5.1 million in 2022, then tumbled by 55.78% to $2.3 million in 2023, then plunged by 84.05% to $359135.0 in 2024, then surged by 222.84% to $1.2 million in 2025, then slumped by 62.11% to $439335.0 in 2026.
• According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $439335.0, $1.2 million, and $410937.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.